Success and Complication Rates After Sacral Neuromodulation for Fecal Incontinence and Constipation: A Single-center Follow-up Study
- Author:
Bernhard WIDMANN
1
;
Christian GALATA
;
Rene WARSCHKOW
;
Ulrich BEUTNER
;
Onder ÖGREDICI
;
Franc H HETZER
;
Bruno M SCHMIED
;
Stefan POST
;
Lukas MARTI
Author Information
- Publication Type:Original Article
- Keywords: Constipation; Electric stimulation; Fecal incontinence; Sacral nerve stimulation; Sacral neuromodulation
- MeSH: Constipation; Electric Stimulation; Electrodes; Fecal Incontinence; Follow-Up Studies; Humans; Prospective Studies; Retrospective Studies
- From:Journal of Neurogastroenterology and Motility 2019;25(1):159-170
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: The aim of this study was to evaluate the sustainability of sacral neuromodulation (SNM) success in patients with fecal incontinence (FI) and/or constipation. METHODS: This is a retrospective analysis of a prospective database of patients who received SNM therapy for FI and/or constipation between 2006 and 2015. Success rates, complications and reintervention rates were assessed after up to 10 years of follow-up. RESULTS: Electrodes for test stimulation were implanted in 101 patients, of whom 79 (78.2%) received permanent stimulation. The mean follow-up was 4.4 ± 3.0 years. At the end of follow-up, 57 patients (72.2%) were still receiving SNM. The 5-year success rate for FI and isolated constipation was 88.2% (95% confidence interval [CI], 80.1–97.0%) and 31.2% (95% CI, 10.2–95.5%), respectively (P < 0.001). In patients with FI, involuntary evacuations per week decreased > 50% in 76.1% of patients (95% CI, 67.6–86.2%) after 5 years. A lead position at S3 was associated with an improved outcome (P = 0.04). Battery exchange was necessary in 23 patients (29.1%), with a median battery life of 6.2 years. Reinterventions due to complications were necessary in 24 patients (30.4%). For these patients, the 5-year success rate was 89.0% (95% CI, 75.3–100.0%) compared to 78.4% (95% CI, 67.2–91.4%) for patients without reintervention. CONCLUSIONS: SNM offers an effective sustainable treatment for FI. For constipation, lasting success of SNM is limited and is thus not recommended. Reinterventions are necessary but do not impede treatment success.
